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524A ABSTRACTS . Special Topics 
Conclusioo: Substantial variations in cost exist for the same surgical procedure when 
pelformed at different institutions. For centers with high surgical costs, evaluating prac- 
tices from other institutions may lead to cost savings. 
1070-54 The Impact of Diabetes on Clinical and Economic 
Outcomes of Percutaneous Coronary Intervention in the 
Elderly: A Population-Based Analysis 
Ameet Bakhai, Mary Ann Clark, Mike Lacey, Elise Pelletier, David J. Cohen, Beth Israel 
Deaconess Medical Center, Boston, MA, Royal Brompton Hospital, London, UK, Boston 
Scientific Corporation, Natick, MA 
Background: Although diabetes mellitus (DM) has been shown to be an important risk 
factor for restenosis in numerous clinical trials, the interaction between DM and both the 
clinical and economic burden of restenosis in an unselected population is unknown. 
Methods: All patients aged 2 65, undergoing initial PCI were identified from the 1999 
Medicare 5% Sample Standard Analytic File and followed to 1 year. Subsequent clinical 
events were tracked through Medicare claims, and medical care costs were assessed 
from the Medicare payment perspective. Clinical restenosis was defined as the occur- 
rence of any repeat revascularization between 1 and 12 months after initial PCI. 
Results: Within this elderly PCI population (n=l0,308, mean age 73.9 yrs), 36.6% were 
diabetic. Crude restenosis rates ware significantly higher for diabetics (11.9% vs. 8.4%, 
p<O.OOl) and remained 32% higher in adjusted analyses (see Table). Restenosis 
increased follow-up medical care costs by $20,745 for DM patients and by $18,365 for 
non-DM patients (pcO.001 for DM vs. non-DM). The attributable l-year costs of resteno- 
sis were $2,469 and $1,543 per patient, for DM and non-DM patients respectively. 
Conclusions: Among unselected, elderly patients undergoing PCI, DM is associated 
with m an increased risk of restenosis and higher costs for treatment of restenosis. 
These findings have important implications for the cost-effectiveness of drug-eluting 
stents in both DM and non-DM populations. 
Table 1. I -Year Climcal and Economic Outcomes 
Outcome 
;3,776) 
Death (%) 12.1 
Clinical Restenosis (96) 11.9 
Repeat PCI (%) 9.2 
CABG (%) 3.3 2.0 
Follow-Up Medical Care DM 
costs 
Non-DM 
Without restenosis 
(BD) 
With restenosis 
(SD) 
Restenosis-related 
costs 
$4,937 53,399 
* $10,408 * $8,126 
$26,168 $22,178 
* $20.899 * $16,478 
$20,745 $18,365 
&In-DM 
(N&,530) 
8.6 
6.4 
7.0 
Adjusted OR 
(95% Cl) 
1.14 
(0.96 _ 1.31) 
1.32 
(1.15 - 1.52) 
1.25 
(1.07 - 1.45) 
1.39 
(1.08 - 1.80) 
Net difference 
$1,530 
$3,961 
$2,462’ 
P 
value 
0.061 
<o.oo 
1 
0.004 
0.012 
P 
ValUe 
<o.oo 
1 
<o.oo 
1 
<o.oo 
1 
1070-55 Estimating the Cost-Effectiveness of Tirofiban for Acute 
Coronary Syndrome Patients Managed in a Relatively 
Low Interventional Setting: The United Kingdom 
Ameet Bakhai, Christos Alexopoulos, David Goldsman, Evo Alemao, Robert Deuson, 
John Cook. Marcus D. Flather, Royal Brompton Hospital, London, United Kingdom, 
Merck&Co., Inc.. Whitehouse Station, NJ 
In the UK. most hioh-risk Datients with non-ST elevation acute coronaw svndromes 
(ACS) are managed without direct access to coronary interventions, leading’to uncer- 
taintv about the cost imDact of GP Ilblllla inhibitors in this relativelv low interventional set- 
ting. We estimated the cost par event avoided &PEA) of tirofiban in this setting. 
Methods: Data from a UK registry (PRAIS-UK. n=l046) for high-risk ACS pts (TIMI 23) 
were used in a decision model with hierarchical outwme rates of death, non-fatal MI, and 
rehospitalization for ACS, with pts managed invasively or non-invasively, with or without 
tirofiban (cost f584 for 4 vials), applying local costs of care. Risk reductions were used 
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from the PRISM-PLUS trial and adjusted for invasive management strategies with results 
of the TACTICS trial. Regression models were fitted for cost estimation with outcomes, 
treatment arms and interactions between them. Sensitivity analyses were performed on 
%‘of pts managed invasively, main cost drivers (e.g. tirofiban, PTCA) and baseline out- 
come rates. 
Limitations: In the absence of a relevant single trial, data from 2 trials were used to 
derive probabilities accepting inevitable differences between trials such as practice pat- 
terns. 
Results: See Table. 
Conclusions: In the UK, treating high-risk ACS pts with tirofiban gives CPEAs of f8.300 
with non-invasive and f12,377 with invasive strategies. supporting the national (NICE) 
guidance for the use of Gp Ilb/llla inhibitors for all such high-risk ACS patients. 
Cost effectiveness rants by Treatment Strategy 
Treatment Strategies 
Tirofiban+Non-Invasive vs. Non- 
Invasive alone 
Events avoided per 100 
patients treated 
6.01 
Cost per event 
avoided 
&a,300 
Tirofiban+lnvasive vs. Invasive 
alone 
4.32 
212,377 
107056 Cost-Effectiveness of Prehospital Thrombolysis 
Everl J. Lamfers , Astrld Schut, Ton E. Hooghoudt. Don P. Hertzberger, Pieter W. 
Stolwiik. Eric Boersma. Freek W. A. Verheud. Ben A. Van Hout. Canisius-Wilhelmina 
I  
Hospital, Nijmegen, The Netherlands, Julius Center, Utrecht, The Netherlands 
Background: Although prehospital fibrinolysis in acute myocardial infarction is associ- 
ated with a time gain of one hour in time to treatment, this strategy has not lead to wide- 
spread application. To guide budget allocations needed for prehospital treatment, a cost 
benefit analysis was made of this treatment strategy. 
Methods: Time intewals were based on data of 736 patients with acute myocardial inf- 
arction: 468 patients treated prehospitally and 268 in-hospitally. For risk assessment, 
data were used from the TIMI-risk score of ST-segment elevation myocardial infarction. 
Two different cost-effectiveness approaches were used: In one method the median time 
gain of prehospital fibrinolysis, compared with in-hospital fibrmolysis, was matched with 
the associated risk reduction calculated on the basis of the literature. Costs of prehospital 
diagnosis and treatment were added to the suwival after 30 days, and cost effectiveness 
was estimated as the additional costs due to prehospital fibrinolysis divided by the num- 
ber of life years gained. In the other method a mathematical model was used to simulate 
patient histories, each drawn from a certain risk profile, whereby two histories were simu- 
lated for each patient. one with prehospital, and one with in-hospital treatment. 
Results In the first model, with a risk reduction of 30% for in-hospital, and 35% for pre- 
hospital treatment, prehospital fibrinolysis resulted I” costs per life year gained at EUR 
2,600. Using the second model, with simulation of patient histories and according risk 
profiles, the average 30.day survival with prehospital fibrinolysls was 93.73% compared 
to 93.32% with in-hospital fibrinolysis. Assuming an average life expectancy of 10 years 
after discharge, this results in an estimated cost per life year gained of EUR 1,837. 
Conclusion: Prehospital fibrinolysis costs EUR t ,800 to 2,800 per life year gained and 
seems, therefore, at least as cost-effective as other evidence-based infarct treatments. 
1070-57 Routine Use of Ramipril Is Cost-Effective After 
Percutaneous Coronary Intervention 
John G. Canto, William B. Hillegass, Contessa Fincher, Rajiv Mallick, The Umversity of 
Alabama at Birmingham, Birmmgham. AL, Wyeth Research, Collegeville, PA 
Background: The Angiotensin-Converting Enzyme Inhibition Post Revascularization 
Study (APRES) found ramipril, in addition to usual care, was associated with lower mor- 
tality and a trend towards fewer non-fatal cardiac events in patients after PCI. 
Methods: A decision analytic model was developed to evaluate the cost-effectiveness of 
ramipril, using only direct medical costs. Efficacy data on cardiac mortality, non-fatal 
events such as acute myocardial infarction, congestive heart failure, and angina pectoris 
associated with ramipril (n=80) or placebo (n=79) were obtained from APRES. Effective- 
ness was defined, in terms of life years gained (LYG) using the persistent benefit 
approach, as the product of within-trial cardiac mortality and projected remaining life of 
11.6 years. Risk reduction in non-fatal events were included to model expected cost 
reductions. Serwtivity analyses were conducted on a range of unit costs, event rates and 
survival duration. Unit costs were derived from national databases (HCUP-III and Medi- 
care) and published literature. Drug costs were based on the Red Book and all costs 
were discounted at 3% !xr war. . 
Results: After accounting for cost offsets due to reduced coronary events, the total 
exmxted incremental costs were 51.896 for ramkxil and 51.434 for olacebo. vieldina a _ _ 
net incremental cost of therapy of $462 per patient discounted over 33 months. Cost of 
therapy translated to $6,079 per death averted, and an incremental cost-effectiveness 
ratio (ICER) of $524 per LYG. The within-trial survival ICER was 2,21O/LYG. In sensitivity 
analyses, the ICER vaned from $G/LYG to $l.O39/LYG using the best and worst case 
scenarios. Global sensitivity showed that the ICER ranged from a net cost saving to 
$l8,982/LYG under the best and worst scenarios. 
Conclusions: The ICER for ramipril is well within the societal willingness-to-pay for an 
additional LYG, even under the worst case scenarios. Routine use of ramipril is cost- 
effective in improving suwival after PCI in patients with chrorw stable angina. 
